Palisade Capital Management LP Acquires Shares of 25,138 Axsome Therapeutics, Inc. $AXSM

Posted by Francis Steltz on Aug 26th, 2026

Palisade Capital Management LP purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 25,138 shares of the company’s stock, valued at approximately $6,153,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kemnay Advisory Services Inc. purchased a new stake in Axsome Therapeutics during the fourth quarter worth about $31,000. Ameriflex Group Inc. purchased a new position in Axsome Therapeutics in the fourth quarter valued at about $37,000. Hollencrest Capital Management lifted its position in shares of Axsome Therapeutics by 400.0% during the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after acquiring an additional 160 shares during the period. Silvant Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the 2nd quarter valued at approximately $66,000. Finally, Farther Finance Advisors LLC boosted its stake in shares of Axsome Therapeutics by 602.6% during the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after acquiring an additional 235 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AXSM shares. BMO Capital Markets initiated coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price target on the stock. Zacks Research raised Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Mizuho boosted their target price on Axsome Therapeutics from $306.00 to $316.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Guggenheim upped their target price on Axsome Therapeutics from $260.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Piper Sandler restated an “overweight” rating and issued a $258.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $267.60.

View Our Latest Analysis on Axsome Therapeutics

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $205.48 on Wednesday. The business’s fifty day moving average price is $230.24 and its two-hundred day moving average price is $206.43. The stock has a market cap of $10.76 billion, a PE ratio of -54.79 and a beta of 0.65. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. Axsome Therapeutics, Inc. has a one year low of $112.90 and a one year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The company had revenue of $218.38 million for the quarter, compared to analysts’ expectations of $221.11 million. On average, analysts forecast that Axsome Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

Insider Activity

In related news, CFO Nick Pizzie sold 33,000 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total value of $7,922,970.00. Following the completion of the transaction, the chief financial officer owned 42,867 shares of the company’s stock, valued at approximately $10,291,938.03. The trade was a 43.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark Coleman sold 643 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the transaction, the director directly owned 30,389 shares of the company’s stock, valued at $7,566,861. The trade was a 2.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 200,766 shares of company stock worth $46,685,646 in the last quarter. Corporate insiders own 20.60% of the company’s stock.

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.